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Abstract
Knee osteoarthritis (KOA) is a common disease in middle-aged and elderly people. Pain is the chief complaint of symptomatic KOA
and a leading cause of chronic disability, which is most often found in medial knees. The aim of this study is to evaluate the efficacy of
pain relief and functional improvement in KOA patients treated with ultrasound-guided adductor canal block (ACB).
This is a 3-month retrospective case-controlled comparative study. Two hundred patients with anteromedial knee pain owing to
KOA that was unresponsive to 3-month long conservative treatments. Ninety-two patients received ACBwith 9mL of 1% of lidocaine
and 1mL of 10mg triamcinolone acetonide (ACB group), and 108 continued conservative treatments (control group). The main
outcomemeasure was visual analog scale (VAS) of the average knee pain level for the past one week. Secondary outcomes were the
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the timed up and go test, numbers of analgesic ingestion
per day, and opioid consumption per day.
During the 3-month follow-up, 86 patients in ACB group and 92 in control group were analyzed. There was no significant
difference, with the exception of the duration of symptoms, between the 2 groups in age, sex, body mass index, and Kellgren-
Lawrence grade. Repeated-measures analysis of variance and post hoc tests showed improvement of VAS (at month 1), WOMAC (at
month 1), and opioid consumption per day (at month 1 and 2) in ACB group. No adverse events were reported.
To our knowledge, this is the first study to assess the efficacy of ACB for patients with KOA. ACB is an effective and safe treatment
and can be an option for patients who are either unresponsive or unable to take analgesics.
Abbreviations: ACB = adductor canal block, KOA = knee osteoarthritis, VAS = visual analogue scale, WOMAC = the Western
Ontario and McMaster Universities Osteoarthritis Index.
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Knee osteoarthritis (KOA) is a common disease in middle-aged
and elderly people. Pain is the chief complaint of symptomatic
KOA and a leading cause of chronic disability [1] which is mostEditor: Helen Gharaei.
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1often found in medial knees. Management of patients with
knee pain requires a combination of pharmacological and
nonpharmacological treatments, including surgical interventions
when necessary.[4]Pharmacological treatments would often be
the first option, and if pain still continues, rehabilitation including
exercises and physical therapies may be added as part of
nonpharmacological interventions, on top of pharmacological
treatments.[5]
The saphenous nerve is the pure sensory branch of the femoral
nerve. It runs laterally to the femoral artery, and then enters the
adductor canal (Hunter canal, or sartorius canal) where it crosses
in front of the femoral artery. The saphenous nerve provides an
extensive cutaneous innervation over the anteromedial side of the
knee, lower leg, and foot.[6] Saphenous nerve block, used in the
leg during the surgical anesthesia,[7] can help increase the success
rate of saphenous nerve block in the adductor canal (adductor
canal block, ACB) when performed with an ultrasound-guided
approach.[8] Recent studies have reported the efficacy of ACB in
the management of analgesia following total knee arthroplasty
[9–12] and post-meniscectomy.[13] In addition, the administration
of ACB may be accomplished also as a single-shot injection after
total knee arthroplasty.[12,14] However, no study has yet reported
the efficacy of ACB for KOA. The aim of this study is to evaluate
the efficacy of ultrasound-guided ACB as a therapeutic option for
refractory anteromedial knee pain owing to KOA.
Diagnosis of  medial compartment knee osteoarthritis, n=292
Follow-up at month 1, 2, and 3, and analysis, n=86
Pain improved, n=50
Refer to surgery, n=16
Loss of follow-up, n=26
Conservative treatment (duplicated counts for multiple 
treatments)
Oral and topical analgesics, n=185
Exercise at institution, n=78
Intra-articular corticosteroid injection, n=42
Hyaluronic acid injection, n=28
Acceptance of ACB
Allocated to ACB group, n=92
- Received ACB
Pain continued, n=200 (refractory medial compartment knee 
osteoarthritis)
Follow-up at month 1, 2, and 3, and analysis, n=92
Refused to follow-up, n=4
In capable of contact , n=5
Admission due to other medical conditions, n=2
Refer to surgery, n=1
Treatment at other clinics, n=4
Corticosteroid injection, n=2
Unknown treatment, n=2
Refusal of ACB
Allocated to control group, n=108
- Continued conservative treatments
Refused to follow-up, n=2
In capable of contact , n=3
Admission due to motor vehicle accident, n=1
Figure 1. Flow diagram indicating progress of subjects through the study.ACB=adductor canal block.
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2.1. Study design and subjects
This is a retrospective case-controlled comparative study. After
the approval of the institutional review board, medical records of
292 patients who were diagnosed with KOA with anteromedial
pain between January 2010 and April 2015 were reviewed. They
were outpatients at the rehabilitation and orthopedic clinics of
the university hospital. All patients underwent a standardized
history-taking, physical examination, blood test, and knee x-rays.
Inclusion criteria were patients diagnosed as having symptomatic
bilateral KOA according to the criteria of the American College
of Rheumatology;[15] grade of Kellgren–Lawrence grading scale
(a scoring tool used to assess the severity of knee osteoarthritis on
a plain radiograph)[16] 2 to 4 of KOA; age 50 years and above;
reporting at least 6-month duration of symptoms; having
matching symptom (anteromedial knee pain) and simple x-ray
findings with KOA; and with direct tenderness on anteromedial
aspect of the knee owing to KOA. Exclusion criteria were the
presence of other obvious knee pathology, such as fracture, or
rheumatic diseases; referred pain from the lower back suggestive
of lumbar radiculopathy; previous surgery to the knee; knee
synovitis; and abnormal sensory perception suggestive of injury
or entrapment of saphenous nerve.
Two hundred ninety-two patients were diagnosed to have
KOA and underwent conservative treatment for at least 3 months
before the ACB (Fig. 1). We prescribed analgesics including
acetaminophen, nonsteroidal anti-inflammatory drugs, tricyclic
antidepressant, selective serotonin and norepinephrine reuptake2inhibitor, tramadol, and opioids. Acetaminophen was prescribed
for first-line use, with nonsteroidal anti-inflammatory drugs and
opioids as second and third lines of treatment according to the
guidelines.[5,17] When pain mitigated, the reverse order was
applied to reduce the dosage. Patients had institutional flexibility
and strengthening exercise of quadriceps with physical therapists
1 or 2 times a week for 4 to 8 weeks, and were educated to carry
out the same exercise at home. Patients who could not
accommodate regular exercise at the hospital were given
educational leaflets and instruction by physical therapists at
each outpatient follow-up. When a patient entered the
inflammatory phase of osteoarthritis such as increased fluid in
the joint, ultrasonography-guided intra-articular corticosteroid
injection with triamcinolone acetonide 20mg was administered.
If despite the conservative treatment, a patient continued to
complain about knee pains with score ≥4 on a visual analog scale
(VAS) of the average knee pain level for the past 1 week, we
recommended ACB explaining also its indication and complica-
tions. Patients were free to choose either the ACB or other
treatment options. Patients were given a choice to unilateral or
bilateral injection depending on the level of pain. Among 200
patients with refractory KOA, 92 opted for ACB (ACB group)
and 108 for conservative treatments (control group) including
analgesics and exercise.2.2. ACB
The patients in the ACB group received an ultrasound-guided
single-shot ACB, based on earlier studies.[18,19] ACB was
Table 1
Baseline characteristics of patients.
ACB group (n=86) Control group (n=92) P
Age, y 66.5±6.1 64.9±6.2 0.073
∗
Sex, men:women 33:53 27:65 0.203†
Duration of symptoms, y 8.1±4.4 6.8±4.1 0.048
∗
Body mass index, kg/m2 29.8±5.1 28.9±4.7 0.228
∗
Kellgren-Lawrence grade, 2:3:4 41:35:10 36:44:12 0.514†
ACB= adductor canal block. Values are expressed as mean± standard deviation except sex and Kellgren-Lawrence grade, which are expressed as n.
∗
Independent t test for between-group comparison (P<0.05).
†x2 test for between-group comparison (P<0.05).
Lee et al. Medicine (2017) 96:12 www.md-journal.comperformed at mid-thigh (midpoint between the knee and the
inguinal crease) by the lead author with ultrasound equipment
(Logiq P6, GE Healthcare, Buckinghamshire, UK) using a 10 to
13Hz high-frequency linear ultrasound transducer which was
placed transverse to the longitudinal axis of the leg. Underneath
the sartorius muscle, the saphenous nerve was identified in a short
axis view as it descends lateral to the femoral artery in the
adductor canal. The lead author injected 9mL of 1% of lidocaine
and 1mL of 10mg triamcinolone acetonide with a 23-gauge 6-cm
long needle.2.3. Outcome measurements
VAS for knee pain intensity, the Western Ontario andMcMaster
Universities Osteoarthritis Index (WOMAC), the timed up and
go test, and numbers of analgesic ingestion per day, and opioidTable 2
Changes of outcome measurements.
ACB group
(n=86)
Control group
(n=92)
VAS score
Month 0 5.3±1.2 5.0±1.4
Month 1 3.6±1.7 5.0±1.6
Month 2 4.2±2.1 4.9±1.7
Month 3 4.4±2.1 4.8±1.9
WOMAC
Month 0 29.5±7.8 27.7±7.9
Month 1 22.6±9.3 26.8±8.2
Month 2 26.0±9.9 26.5±8.2
Month 3 26.0±6.7 25.0±8.2
No. of analgesic ingestion per day
Month 0 2.5±1.3 2.3±1.3
Month 1 2.3±0.8 2.4±1.1
Month 2 2.1±0.8 2.2±1.4
Month 3 2.0±1.0 2.2±1.2
Opioid consumption per day, mg
Month 0 9.1±15.5 10.2±16.1
Month 1 4.1±9.3 10.4±16.9
Month 2 4.6±9.4 10.5±16.8
Month 3 6.7±11.7 9.6±15.7
Timed up and go test, sec
Month 0 15.4±6.0 13.9±4.5
Month 1 14.3±5.1 13.6±3.8
Month 2 14.1±4.6 13.5±3.8
Month 3 13.6±4.4 13.0±3.3
ACB= adductor canal block, VAS= visual analogue scale, WOMAC=Western Ontario and McMaster U
∗
Repeated-measures analysis of variance for group-by-time interaction (P<0.05).
† If the repeated-measures analysis of variance for group-by-time interaction was significant, post hoc
3consumption per day were compared for pre-, and 1, 2, and 3
months post-injection. All outcome measurements were evaluat-
ed by the lead author. The primary outcome measure was VAS of
the average knee pain level for the past 1 week. Patients answered
the question “With respect to the worst pain you have
experienced in your life, what was the average level of your
knee pain in the past one week?? by placing a mark somewhere
along the 10-cm horizontal line between 2 end-points (left: “No
pain" and right: “the worst imaginable pain."WOMAC is a self-
reporting questionnaire for patients with KOA, which consists of
24 items that are divided into 3 subscales: pain (5 items), stiffness
(2 items), and physical function (17 items).[20] The timed up and
go test is a reliable test with adequate minimal detectable change
for clinical use in individuals with KOA.[21,22] Numbers of
analgesic ingestion per day were measured based on the average
number of analgesics patients have taken per day during the pastP, group-by-time
interaction
∗
P, between-group
comparison†
<0.001
∗
0.072
<0.001†
0.018
0.209
<0.001
∗
0.142
<0.001†
0.708
0.399
0.372
<0.001
∗
0.647
0.002†
0.004†
0.154
0.062
niversities Arthritis Index. Values are expressed as mean± standard deviation.
tests (Bonferroni) was conducted for between-group comparison (P<0.0125).
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value of opioids consumed by patients per day, which has been
converted to the morphine equivalent dose.2.4. Statistical analysis
After a normality test, we compared 2 groups in terms of age, sex,
duration of symptoms, Kellgren-Lawrence grade, and body mass
index by performing independent t- or x2 analysis. The effect of
injection during 3 months was evaluated with repeated-measures
analysis of variance. If the repeated-measures analysis of variance
for group-by-time interaction was significant, post hoc tests
(Bonferroni) of between-group comparison were conducted. The
P value was adjusted using the Bonferroni method. Significance
was accepted for P values of <0.05. All these analyses were
performed using SPSS statistical software, version 22 (IBM,
Armonk, NY).3. Results
Out of a total of 200 refractory KOA patients, 92 received ACB
and 108 current conservative treatments (Fig. 1). Of them,
respectively 86 and 92 patients were included in the final analysis.
Among the ACB group, 70 patients (81.4%) received bilateral
and 16 (18.6%) unilateral ACB injection. Table 1 lists the
baseline characteristics of the study subjects. There were no
statistical differences between the 2 groups in terms of age, sex,
body mass index, and Kellgren-Lawrence grade, except for the
duration of symptoms which lasted longer in the ACB group (8.1
±4.4 vs. 6.8±4.1 years). Table 2 shows the changes of outcome
measurements of ACB and control groups. Repeated-measures
analysis of variance showed significant effect of time in all
outcome measurements (P<0.001). This means that compared
to pretreatment, all outcome measures improved significantly in
both groups with time. Group-by-time interactions were
significant for VAS, WOMAC, and opioid consumption per
day between groups (P<0.001). Post hoc tests for between-group
comparisons revealed that there are significant differences in VAS
and WOMAC at month 1, and opioid consumption per day at
month 1 and 2. There were no adverse events reported such as
bleeding, infection, cellulitis, or weakness.4. Discussion
ACB has often been used to control pain after the anesthesia and
operation of the lower leg[7,9–12,14] and has been reported to be
effective on knee pains caused by saphenous nerve neuropathy
and postmeniscectomy pain.[13,23] To our best knowledge, this is
the first study to evaluate the efficacy of ACB in KOA. In this 3-
month follow-up study, ACB was used to treat patients who had
anteromedial knee pain owing to KOA but failed 3-month-long
conservative treatments. The ACB group showed improvement in
VAS (at month 1), WOMAC (at month 1), and opioid
consumption per day (at month 1 and 2), compared to the
control group. KOA is very common and the medial compart-
ment is affected most frequently than other areas.[2,3] ACB is
easily performed at the outpatient clinic and can reduce pain up
to at least 1 month for patients with KOA who continue to show
no response to analgesics.
Adductor canal is an aponeurotic tunnel in the middle third
of the thigh composed medially of the adductor longus,
laterally of the vast us medialis, and interiorly of the sartorius
and the subsartorial fascia. ACB blocks the largest sensory4contributions from the femoral nerve to the knee, the
saphenous nerve.[10,24] In addition to the saphenous nerve,
the adductor canal contains the nerve to the vastus medialis, the
medial femoral cutaneous nerve, the medial retinacular nerve,
and the articular branches from the posterior division of
obturator nerve which enters the distal part of the canal. Except
for the nerve to the vastus medialis, these branches have a sole
sensory function, and most of them play a major role in the
sensory innervation of the knee region. Many trials have
recently hypothesized that administration of local anesthetic
into the ACB could be a useful option for postoperative
analgesia after total knee arthroplasty.[9–12] Since KOA is a
disease of the entire knee joint, the cause of knee pain can
origin not only from degenerative changes of cartilages and
bones, such as cartilage wearing, sclerosis of subchondral bone,
and osteophytes, but also from tears and subluxation of
menisci, sprain of ligaments, tendinitis, bursitis, and
synovitis.[1,25–27] As part of its mechanism, ACB is thought
to interrupt the pain signal, which originates from various
lesions of KOA.
The saphenous nerve departs from the adductor canal in the
distal thigh, piercing the fascia between the sartorius and gracilis
muscles to become subcutaneous.[30] From this point, the
saphenous nerve is first divided distally into 2 branches, sartorial
and infrapatellar,[28,29] and then again into multiple small
subcutaneous branches. This makes it hard to identify the nerve
in more distal locations. In a cadaveric study, the authors found
that the saphenous nerve divides into 2 branches from outside the
adductor canal at a mean of 2.7cm proximal to the base of the
patella. They reported the block at this location to be
successful.[8] In the present study, we blocked the saphenous
nerve in the middle of the adductor canal. Ultrasonography was
used to identify the entry point of the needle, on average 10cm
proximal to the knee crease. This is an ideal location to block the
nerve while using the femoral artery as a landmark. It is also
proximal enough to ensure the blocking of both main branches,
sartorial and infrapatellar.[18]
Although no difference was found between the 2 groups in
terms of the number of analgesic (opioids included) ingestion per
day, the ACB group was found to have consumed less opioids per
day in month 1 and 2. The difference came from the fact that we
had reduced the opioids first among other prescribed analgesics
when pain resided and educated the patients to switch to
acetaminophen or nonsteroidal anti-inflammatory drugs accord-
ing to the treatment guidelines.[5,17] Therefore, it was possible for
opioid consumption to go down but not the total number of
analgesic intake. Although claiming the long-term effect of a
single round of ACB in lowering the opioid dosage may be
farfetched, there is a clear advantage of ACB in reducing the
usage of opioid at least during the first 2 months. Taking into
account the common adverse events of opioids that can occur in
elderly patients (cognitive impairment, delirium related falls and
fractures, depression, cardiovascular events, and pneumo-
nia),[31,32] it may be possible to consider a combined therapy
of ACB over additional opioid intake for patients who complain
transient acute pain.
We used 10mL of anesthetic for ACB in this study. The volume
of anesthetic that is going to be used needs to be considered as one
of the factors impacting the analgesia and side effects of ACB.
Although not enough of the anesthetic may result in an insufficient
analgesic effect, too much can lead to an undesirable anesthesia or
weakness owing to the blocking of the femoral or sciatic nerves, as
the adductor canal is connected proximally to the femoral triangle
Lee et al. Medicine (2017) 96:12 www.md-journal.comand extended to the adductor hiatus to distally connect with the
popliteal fossa.[33,34] Previous trials that administered ACB after a
knee surgery have used 10 to 30mL.[10,13,35] ACBs that used
volume of 20mL have reported sufficient pain relief while at the
same time finding little or no weakness owing to femoral nerve
blockades.[35–37]However, recent studies have reported that evena
volume of <20mL may affect the femoral or sciatic nerve or
branches. In one cadaveric study, 15mL of injectate that was
administered into the adductor canal spread proximally to the
femoral triangle and distally to the adductor hiatus.[34] And the
results of a study that evaluated the electromyographic activity of
vastus medialis and lateralis and muscle weakness of quadriceps
femoirs by administering 10, 20, and 30mLof 1% lidocaines to 20
volunteers showeda strongassociationbetweenvolumeandvastus
medialis effects. A volume of 30mL resulted in an affection in all
subjects, a volume of 20mL resulted in an affection in 84% of the
subjects,whereas a volumeof 10mLonly resulted in anaffection in
35% of the subjects.[38] We asked patients whether they had any
weakness of quadriceps beforeACBandupon follow-up; however,
none of the patient reported any weakness. Still, as no quadricep
muscle power or electromyographic activity was used for the
measurement, we were not able to identify whether the volume
usedhad impacted femoral or scitic nerves.As there is no consensus
on how different volumes affect analgesic effect and quadriceps
weakness, patients should be monitored for motor strength to
reduce the risk of fall.
The greatest limitation of this study lies in the fact that it is a
retrospective study and that the group allocation was not
randomized. Patients chose to take the therapy according to
their own will, and no randomization process was involved.
Nonetheless, it has relatively low drop-out rate (11.0% in
total), a large sample size (N=178), enough follow-up period
(3 months) to monitor the effect of ACB, and consistent
baseline characteristics (age, sex, body mass index, and
Kellgren-Lawrence grade) across both groups compared. It
also includes at least 3 rounds of follow-ups (at month 1, 2, and
3) after ACB to monitor whether other treatments have been
received, which was a part of the effort to reduce bias as much
as possible. Second, the aim of this study was to evaluate the
changes in the long-term evaluation (1, 2, and 3 months) of
pain and function of ACB; therefore, the outcome measurement
immediately after ACB was not measured. However, the fact
that sensory evaluation was not performed to confirm the
success of sensory blockade can be a limitation. Third, not only
are there many factors impacting pain including psychological
and environmental factors, drugs, stress, and concomitant
diseases, but also great changes that take place between these
factors with time. In an effort to take these into consideration,
we tried to identify mid-term changes in pain rather than
immediate changes claimed on the day of the follow-up visit.
VAS of the average knee pain level for the past 1 week was
therefore used as our tool. However, this tool may have a
greater recall bias than the ordinary VAS.
In conclusion, this study looked into the possibility of ACB as
an alternative treatment for anteromedial knee pain owing to
KOA. Although a palliative treatment, and not one that stops the
progression of the disease or changes its natural course, ACB can
be an option for patients with refractory KOA who cannot take
or are not responsive to analgesics. However, to prove the
efficacy of ACB, further studies on prospective randomized
controlled trials would be needed to overcome the limitations
mentioned in the discussions.5Acknowledgment
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